IGHE and neoplasm: Therefore, pipelines to rapidly and cost-effectively clone, express and purify IgE antibodies for pre-clinical study have been developed [32,35,36,37,38,39] and indeed, in the field of AllergoOncology [25,26,34,40,41], in vitro and in vivo data (described below) have demonstrated the promising therapeutic efficacy of tumour-targeting IgE antibodies.